Bristol-Myers Squibb Aktie News

At the current price, investors are paying little for Bristol Myers' pipeline.

Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite cost-saving initiatives and the Hess acquisition, leading to subdued dividend growth. Dividend increases in January will generally be modest, with select companies like Fastenal, S&P Global, and C...

This drug company offers a decent balance of risk and reward, with a 4.6% yield and a payout ratio comfortably below 100%. This medical device company has a 2.9% yield and is nearing Dividend King status.

BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 56.5% of revenues, temporarily offsetting legacy declines while lending credibility to the thrice raised FY2025 guidance. Otherwise, BMY faces numerous Patent cliffs for Opdivo/Eliquis and the Medic...

Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY and overtaking legacy drugs, supporting a bullish outlook. Despite modest 3% total revenue growth, BMY maintains robust margins, strong cash flow, and a 4.65% dividend yield, enhancing its defensive ...

Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of exclusivity risks, BMY's growth portfolio delivered 18% growth in Q3 and now exceeds 50% of business mix. Robust free cash flow margins (>30%) and a 4.7% yield provide BMY investors with attractive...

Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus, reflecting pipeline strength. Shares trade at a discount to peers with a 14% FCF yield, while multiple late-stage drugs and recent acquisitions support long-term growth.

Bristol-Myers Squibb (BMY) is transitioning from a perceived value trap to a growth-focused, diversified pharmaceutical company. BMY's growth portfolio grew 18% YoY in Q3, offsetting legacy drug declines and supporting a raised 2025 revenue outlook of $47.5–$48.0 billion. Trading at less than 8x FCF and offering a 4.65% dividend yield, BMY appears undervalued relative to peers on key profitabil...